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Abstract Increasing evidence exists that iron overload, a
common ﬁnding in chronic hepatitis C virus (HCV)
infection, plays an important role in the pathophysiology of
this disease. The mechanisms by which iron excess induces
liver damage along with the beneﬁt of iron depletion via
phlebotomy on biochemical and histological outcomes in
patients with chronic HCV infection have been discussed
in this review. Finally, we focus on the effect of iron
reduction on the rate of response to interferon antiviral
therapy.
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Introduction
Hepatitis C virus (HCV) infection, which affects nearly 2%
of the human population, is a major cause of liver disease
worldwide. Following acute HCV infection, a chronic state
is established in as many as 80% of infected individuals.
Although many subjects carrying the virus remain
asymptomatic, chronicity is often accompanied by altered
liver function and progressive liver disease and culminates
in cirrhosis or hepatocellular carcinoma in up to 20% of
infected individuals [1].
Mild-to-moderate iron overload is a common ﬁnding
among patients with chronic HCV infection; indeed, up to
30–40% of them may show increased serum transferrin-
iron saturation and serum ferritin or increased hepatic iron
concentration [2, 3]. On the other hand, elevated iron
indices have been correlated with a progression of the liver
disease and a decreased response to antiviral therapy [4–9].
The association between iron overload and chronic HCV
infection, along with the effect of iron depletion on the
course of chronic HCV infection and the response to
antiviral therapy, has been addressed in this review.
Sources
We ﬁrst performed an electronic search on MEDLINE,
EMBASE, SCOPUS, and OVID databases without tem-
poral limits using different combinations of the following
keywords: ‘‘phlebotomy,’’ ‘‘iron depletion,’’ ‘‘iron over-
load,’’ ‘‘iron reduction,’’ ‘‘hepatitis C virus infection,’’
‘‘HCV,’’ ‘‘chronic hepatitis C,’’ ‘‘antiviral therapy,’’
‘‘interferon,’’ and ‘‘ribavirin.’’ In addition, the biblio-
graphic references of all retrieved studies and reviews were
assessed for additional reports of clinical trials. Only full-
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Iron overload and chronic HCV infection
The mechanism of hepatotoxicity of iron accumulation in
chronic HCV infection is still unclear. The deposition of
iron predominantly within Kupffer cells and portal mac-
rophages, the correlation between hepatic necroinﬂam-
matory activity and iron accumulation, and the reduction of
hepatic iron content following response to interferon (IFN)
therapy suggest that hepatic iron overload is the result of
hepatocyte necrosis, which leads to release of ferritin from
hepatocytes and subsequent uptake by macrophages
[10–12]. However, another possible mechanism to explain
the elevated iron stores could be the increased intestinal
iron absorption. Indeed, recent investigations have found
decreased levels of hepcidin (a peptide hormone produced
in the liver that has an inhibitory effect on iron absorption)
and increased levels of transferrin receptor 2 (which is
located on the hepatocyte membrane and is involved in the
uptake of iron by hepatocytes) in chronic HCV infection
[13]. Thus, the resulting effect of these abnormalities could
be an increased delivery of iron to hepatocytes from
macrophage iron stores and intestinal mucosa.
Excess iron increases the formation of reactive oxygen
species leading to lipid peroxidation, damage to protein
and DNA, and thereby to cell membranes and genomic
damage. Reactive oxygen species, which include hydroxyl
radicals, may cause hepatic stellate cell activation and
proliferation and upregulate synthesis of smooth muscle
actin and collagen, thus contributing to hepatic ﬁbrogenesis
[11, 14, 15]. In vitro studies also suggest that iron depo-
sition in hepatocytes enhances HCV replication, thus
facilitating the viral infection in the liver [16]. Moreover,
these hydroxyl radicals are known to generate pro-
mutagenic bases, such as 8-hydroxy-20-deoxyguanosine
(8-OHdG), which have been implicated in spontaneous
DNA mutagenesis and carcinogenesis [12].
Finally, hemochromatosis gene mutations could play a
role in the pathogenesis of iron overload among patients
with chronic HCV infection [17]. Indeed, after the initial
observation by Smith and colleagues [18] that HCV-
infected patients who were carriers of C282Y mutation had
higher serum ferritin levels than patients homozygous for
the wild type of the HFE gene, several other reports have
found that heterozygous HFE mutations are more frequent
and are associated with increased iron storage among
patients with chronic HCV infection [19–24]. However,
studies examining the relationship between HFE mutations
and disease progression in chronic HCV infection have
given conﬂicting results. Indeed, while some studies have
found a positive correlation between HFE mutations and
the severity of liver disease [19, 22, 25–30], others failed to
found such association [31–36]. Methodological- or pop-
ulation-based differences among studies could account for
these discrepant ﬁndings [37]. For instance, Tung and
colleagues [19] studied the liver histology in 316 patients
with chronic HCV infection at various stages and found
that the presence of HFE mutations was independently
associated with iron loading and advanced ﬁbrosis in
patients with compensated liver disease. In contrast,
Thorburn and colleagues [31] performed liver biopsies in
164 chronically HCV-infected patients and observed that
the carriage of HFE mutation did not have a role in the iron
accumulation or the progression of liver disease.
The effect of iron depletion on liver status in chronic
HCV infection
Several groups have evaluated the effects of iron reduction
on chronic HCV infection [38–46]. The majority of the
studies performed phlebotomies of 400–500 ml of whole
blood every 1 or 2 weeks until the development of an iron-
deﬁcient anemia. Hayashi and colleagues [39] ﬁrst reported
that iron reduction performed by repeated venesection led
to normalization of serum alanine aminotransferase (ALT)
levels in 5 of the 10 patients. However, serum ALT levels
signiﬁcantly decreased in all patients (from 152 ± 49 to
55 ± 32 U/L, P\0.001). According to a report by
Piperno and colleagues [41], serum ALT levels signiﬁ-
cantly improved in 32 iron-depleted patients with chronic
HCV infection. Similar results were subsequently reported
by other groups with phlebotomy alone [42–45]. However,
no signiﬁcant reduction in serum HCV RNA levels was
observed [42, 46]. The long-term effect of phlebotomy on
biochemical and histological parameters of chronic HCV
infection was addressed by Yano and colleagues in 25
patients undergoing a 5-year maintenance phlebotomy
program [47]. Interestingly, the authors found that the
mean serum ALT levels decreased signiﬁcantly during the
initial phlebotomy program (from 117 to 75 U/l, P\0.05)
and this improvement persisted during the study period.
Furthermore, phlebotomies were able to prevent the pro-
gression of liver histology because the severity of liver
ﬁbrosis (staging score) decreased from 2.3 to 1.7
(P\0.05) in the iron-reduction group, whereas the mean
values increased from 1.7 at baseline to 2.0 at the end of
follow-up in controls (P = NS). Likewise, the severity of
inﬂammation (grading score) remained unchanged in the
study group (1.8 vs. 2.0, P = NS) but progressed in the
control group (2.0 vs. 2.9, P\0.005). Thus, the authors
concluded that long-term maintenance of iron depletion is a
safe and effective alternative to IFN treatment and could be
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123particularly indicated for those patients who do not respond
to antiviral therapy or cannot tolerate such drugs.
Recently, Alexander and colleagues [48] found that iron
depletion was associated with a biochemical response in
22% of patients who did not respond to IFN monotherapy
and that, among patients with serum ALT normalization,
there was a signiﬁcant reduction of serum markers of liver
ﬁbrosis (procollagen III peptide). Kaito and colleagues [49]
found that iron-reduction therapy by phlebotomy signiﬁ-
cantlyreducedlipidperoxidationandoxidativestress,which
mediate the deleterious effect of iron overload on the liver.
Finally, other groups have demonstrated that the asso-
ciation of a low-iron diet to phlebotomy has an additional
effect in removing iron-induced oxidative stress [50, 51].
Indeed, in a study conducted by Kato and colleagues [51],
34 patients with chronic HCV infection unresponsive to
IFN therapy were maintained in an iron-depleted state with
phlebotomy and a low-iron diet for 6 years. This therapy
was associated with a high rate of biochemical response
(65%), improvement in liver histology, and reduction in
hepatic levels of 8-OHdG, a marker of oxidant stress. In a
recent cohort study, the same authors demonstrated that
long-term phlebotomy with a low-iron diet therapy reduced
the risk of progression of chronic HCV infection to hepa-
tocellular carcinoma [52].
Table 1 summarizes the results of the most important
studies on the effect of iron depletion by phlebotomy on
chronic HCV infection.
The effect of iron depletion on response to antiviral
therapy
Based on the ﬁndings that iron overload has been associ-
ated with more advanced liver disease and that increased
hepatic iron concentration is predictive of a poor response
to IFN monotherapy [4, 9], some investigators have eval-
uated the impact of phlebotomy on the response to IFN
therapy in chronic HCV infection [38, 41, 46, 53–60]. In a
study on 81 patients with chronic HCV infection, Piperno
and colleagues [41] found that iron depletion by phlebot-
omy did not improve the response to IFN-a in both naı ¨ve
and nonresponder patients. Similarly, Herrera [46] and
Guyader and colleagues [53] concluded that iron depletion
was not effective in inducing a virologic response in
patients with chronic HCV infection who failed to respond
to IFN therapy. In a multicenter, prospective, randomized
controlled trial on 96 patients with chronic HCV infection
who were nonresponders to IFN, Di Bisceglie and col-
leagues [55] compared iron reduction by phlebotomy with
iron reduction plus retreatment with IFN and concluded
that although prior phlebotomy therapy did not improve the
rate of sustained virologic response to IFN retreatment, it
resulted both in a decrease of serum ALT levels and in a
slight improvement in liver histopathology. In contrast,
Tsai and colleagues [54] observed that IFN retreatment
preceded by iron depletion rescued 15% of previously
nonresponder patients. In a multicenter study, Fargion and
colleagues [56] randomized 114 previously untreated
patients with chronic HCV infection to receive IFN alone
or phlebotomy followed by IFN therapy and found that iron
removal improved the rate of response to IFN. In fact,
patients in the combination group (phlebotomy followed by
IFN) had a 2.32 odds ratio (95% conﬁdence inter-
val = 0.96–6.24) of obtaining a sustained virologic
response in comparison with patients in the IFN-alone
treatment group. Similarly, the reduction of necroinﬂam-
matory activity and the improvement of the response to
IFN was observed by Carlo et al. [57] in the group of
patients who underwent phlebotomy before antiviral
therapy.
Three randomized controlled studies compared the
combination of iron depletion plus IFN with IFN alone
[57–59]. Van Thiel and colleagues [58] showed that the
combination treatment was effective in previous IFN
nonresponders (60% of sustained virologic response in the
combination group compared with 13% in the IFN-alone
group). However, the intensiﬁed IFN regimen used in this
Table 1 Summary of the most important studies on the effect of iron depletion by phlebotomy on chronic hepatitis C virus infection
Author [ref] Number of
patients
Characteristics Results
Hayashi et al. [40] 40 40 naı ¨ve Phlebotomy signiﬁcantly reduced mean ALT levels
Sartori et al. [42] 24 12 IFN NR, 12 naı ¨ve Reduction of ALT levels and inﬂammatory grading score, suppression
of the progression of staging score for ﬁbrosis
Yano et al. [43] 33 NI Phlebotomy signiﬁcantly reduced ALT
Tanaka et al. [44] 22 NI Phlebotomy signiﬁcantly reduced ALT, AST, and a-fetoprotein levels
Yano et al. [47] 25 22 IFN NR, 3 naı ¨ve Reduction of ALT levels, improvement of liver inﬂammation, and suppression
of the progression of liver ﬁbrosis
Alexander et al. [48] 18 18 NR Biochemical response was accompanied by a reduction of markers of ﬁbrogenesis
Abbreviations: IFN, interferon; NR, nonresponders; NI, not indicated; ALT, alanine aminotransferase; AST, aspartate aminotransferase
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123study (5 million units daily) could account for the high rate
of virologic response observed. Fong and colleagues [59]
observed a higher rate of sustained virologic responses in
naı ¨ve patients treated with phlebotomy before and during
IFN treatment than those receiving IFN alone (29% vs.
5%). In a similar trial, Fontana and colleagues [60] showed
that iron reduction via therapeutic phlebotomy improved
the virologic and histologic response to IFN therapy.
Recently, Desai et al. [61] performed a meta-analysis of six
prospective randomized controlled trials and concluded
that phlebotomy improves the response to IFN in patients
with chronic HCV infection. Table 2 summarizes the most
important studies analyzing the effect of iron depletion and
IFN in the treatment of chronic HCV infection.
Conclusions
On the whole, the literature data suggest that iron depletion
via phlebotomy improves biochemical and histological
outcomes in patients with chronic HCV infection. In
addition, a number of studies have documented that com-
bining iron depletion with IFN monotherapy may improve
the rate of virologic responses in previously untreated and
nonresponder patients.
Of note, recent investigations have found that hepatic
iron concentration does not inﬂuence the response to
antiviral therapy with IFN plus ribavirin [62, 63]. In
addition, an iron-deﬁciency anemia due to repeated phle-
botomies could be a risk factor for unsuccessful outcome of
the antiviral treatment because of dose reduction of riba-
virin. Thus, it will be interesting to see the results of future
randomized controlled trials assessing the efﬁcacy of
combining iron-depletion therapy with pegylated IFN and
ribavirin in chronic HCV infection.
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